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Abstract
Exosomes are membrane-bound vesicles found in all biological fluids. AML patients’ plasma collected at diagnosis contains
elevated exosome levels relative to normal donor (ND) plasma. The molecular profile of AML exosomes changes in the
course of therapy and may serve as a measure of disease progression or response to therapy. However, plasma contains a
mix of exosomes derived from various cell types. To be able to utilize blast-derived exosomes as biomarkers for AML, we
have developed an immunoaffinity-based capture method utilizing magnetic microbeads coated with anti-CD34 antibody
(Ab). This Ab is specific for CD34, a unique marker of AML blasts. The capture procedure was developed using CD34+
exosomes derived from Kasumi-1 AML cell culture supernatants. The capture capacity of CD34microbeads was shown to
linearly correlate with the input exosomes. A 10 uL aliquot of CD34 microbeads was able to capture all of CD34+ exosomes
present in 100–1,000 uL of AML plasma. The levels of immunocaptured CD34+ exosomes correlated with the percentages of
CD34+ blasts in the AML patients’ peripheral blood. The immunocaptured exosomes had a typical cup-shaped morphology
by transmission electron microscopy, and their molecular cargo was similar to that of parental blasts. These exosomes were
biologically-active. Upon co-incubation with natural killer (NK) cells, captured blast-derived exosomes down-regulated
surface NKG2D expression, while non-captured exosomes reduced expression levels of NKp46. Our data provide a proof-of-
principle that blast-derived exosomes can be quantitatively recovered from AML patients’ plasma, their molecular profile
recapitulates that of autologous blasts and they retain the ability to mediate immune suppression. These data suggest that
immunocaptured blast-derived exosomes might be useful in diagnosis and/or prognosis of AML in the future.
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Introduction
Although advances in acute myeloid leukemia (AML) therapy
have considerably improved initial response rates and patients’
quality of life, survival rates remain low, largely due to disease
relapse [1,2]. The failure of conventional therapies to control
leukemic relapse has stimulated the search for novel, more
effective therapeutic approaches. Recently, tumor-derived exo-
somes (TEX) have emerged as one of the key modulators of
immune evasion/suppression in cancer, including hematologic
malignancies [3–6]. In view of emerging evidence for the critical
role of the host immune system in cancer progression, evaluation
of the impact TEX exert on the disease activity, severity and
response to therapy in AML is of great interest.
Exosomes are 30 to 100 nm intraluminal vesicles (ILV)
generated by inward budding of endosomal multivesicular bodies
(MVB). MVB traffic to and fuse with the plasma membrane,
releasing ILV into the extracellular space [7]. The exosomal cargo
includes proteins/glycoproteins expressed on the cell membrane as
well as molecules and soluble factors present in the cytosol of
parental cells. Exosomes are found in all biological fluids,
including urine, plasma or ascites. While exosome secretion occurs
under physiologic conditions, and all cells are capable of their
release, tumor cells are avid exosome producers. Importantly,
exosome fractions obtained from plasma of cancer patients are
enriched in molecules which play a role in tumor proliferation,
immune escape and metastasis [8–12].
Plasma of newly-diagnosed AML patients contains higher levels
of exosomal protein (in mg/mL plasma) than normal donors’ (ND)
plasma [13,14]. Also, AML exosomes have a distinct molecular
profile. In addition to conventional exosome markers, such as
tetraspanins, they contain membrane-associated TGF-b1, MICA/
MICB, FasL and myeloid blast markers, CD33, CD34 and
CD117 [13]. When tested ex vivo, AML exosomes decreased
natural killer (NK)-cell cytotoxicity by down-regulating NKG2D
expression levels in normal NK cells [13,14]. Antibody neutral-
ization of TGF-b1 carried by AML exosomes partially restored
NK-cell functions, suggesting that exosome-associated TGF-b1 is
in part responsible for NK-cell dysfunction in AML. Thus,
exosomes present in AML patients’ plasma have a potential to
modulate innate immune responses and could influence disease
progression or response to therapy.
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Exosomes are purified from biological fluids using differential
centrifugation, ultrafiltration, size-exclusion chromatography and
high-speed ultracentrifugation [13,14]. However, exosomes isolat-
ed from human plasma are largely derived from normal cells, such
as e.g., platelets, which are known to be strong exosome producers
[15]. TEX, if present in plasma, probably account for only a
fraction of all isolated exosomes. We hypothesize that AML blast-
derived exosomes are more biologically active than exosomes
produced by normal cells and that they largely mediate immune
suppression. To be able to perform molecular analyses of blast-
derived exosomes, establish their clinical significance and deter-
mine their role as potential biomarkers of disease progression/
relapse, it is first necessary to separate them from plasma exosomes
derived from normal cells. Because AML blast-derived exosomes
carry a unique set of membrane-associated molecules, which
mimic those present in the membrane of AML blasts, they can be
distinguished and separated from non-blast exosomes present in
the same plasma. Based on this principle, we have developed an
immunoaffinity-based capture method for AML blast-derived
exosomes using microbeads coated with anti-CD34 antibody (Ab).
Our data provide a proof-of- principle that blast-derived exosomes
can be quantitatively recovered from AML patients’ plasma and
that their molecular profile recapitulates that of the blasts. These
isolated exosomes are biologically-active, mediate immune sup-




A human CD34+ leukemic cell line (Kasumi-1) was purchased
from American Type Culture Collection (Manassas, VA, USA)
and cultured in RPMI supplemented with 2 mM/ml L-glutamine,
100 U/ml penicillin, 100 ug/ml streptomycin and 10% (v/v) fetal
bovine serum (FBS). All reagents were purchased from Invitrogen
(Grand Island, NY, USA). FBS was depleted of bovine exosomes
by ultracentrifugation at 100,0006g for 3 hrs. Conditioned media
(CM) were collected from 48–72 hr sub-confluent cell cultures
after centrifugation at 10,000 g for 30 min and concentrated using
a Vivacell 100 unit (Sartorius Corp, Bohemia, NY, USA).
Concentrated CM was filtered using a 0.22 um syringe-filter unit
and used for exosome isolation.
Plasma of AML patients and healthy donors
Samples of venous blood (20–50 mL) were obtained from
newly-diagnosed AML patients prior to any treatment and from
age-matched healthy volunteers. All subjects participating in this
study signed an informed consent approved by the Institutional
Review Board of the University of Pittsburgh (IRB #960279, IRB
#0403105 and IRB #0506140). Peripheral blood was collected
into heparinized vacutainer tubes, and the samples were hand-
carried to the laboratory. Plasma was centrifuged at 10006g for
10 min to remove blood cells and cell fragments. Clear plasma was
collected and immediately used for exosome capture or aliquoted
into vials, which were stored in liquid N2. Frozen and thawed
plasma was centrifuged at 10,000 g for 30 min and used for
exosome isolation and for immunoaffinity capture as described
below.
Exosome isolation from plasma or cell supernatants
Exosomes were isolated from CM of cultured cells or from
clarified plasma of ND or AML patients as previously described
[13,14] with minor modifications. Briefly, following centrifugation
at 10,0006g for 30 min, aliquots of plasma (up to 9 mL) were
passed through a 0.22 mm pore size filter and applied to Bio-Gel
A50 m columns (Bio-Rad Laboratories, Hercules, CA, USA)
packed with Sepharose 2B (Sigma-Aldrich, St. Louis, MO, USA).
The column was eluted with phosphate buffered saline (PBS).
Fractions between 10 and 28 mL (the void volume peak), which
contained proteins of more than 50 million kDa, were collected
into a Beckman Optiseal Centrifuge Tube and centrifuged in a
Beckman Optima LE-80K Ultracentrifuge (Beckman Coulter,
Atlanta, GA, USA) at 100,0006g for 2 h at 4uC. The pellet was
resuspended in PBS (200 mL) and analyzed using a protein assay
kit (Bio-Rad Laboratories, Hercules, CA, USA).
Immunoaffinity capture of exosomes from plasma
To isolate blast-derived exosomes from plasma of patients with
CD34+ blasts, the CD34 microbead kit (Miltenyi Biotec, Auburn,
CA, USA) was used. From 0.1 to 1 mL of freshly-thawed plasma
was used for immune capture. Exosomes captured on CD34 Ab-
coated magnetic beads were recovered from the magnetic column
by eluting with Tris Buffered Saline (TBS) as described by the
manufacturer (MS column, Miltenyi Biotec, Auburn, CA, USA).
Exosome-coated beads were pelleted by centrifugation at
10,0006g for 30 min. Captured exosomes were visualized by
transmission electron microscopy (TEM), co-cultured with NK
cells or lysed in 2x Laemmli sample buffer for Western blot
analyses. In separate experiments, CD61+ exosomes were also
captured from patients’ plasma using CD61 microbead kits
(Miltenyi Biotec, Auburn, CA, USA) to capture and remove
platelet-derived exosomes.
Transmission electron microscopy
TEM was performed at the Center for Biologic Imaging at the
University of Pittsburgh. Freshly-isolated exosomes were put on a
copper grid coated with 0.125% Formvar in chloroform. The grids
were stained with 1% v/v uranyl acetate in ddH2O and the
samples were examined immediately. A JEOL 1011 transmission
electron microscope was used for imaging.
Western blots
Isolated or immunocaptured exosomes were tested for the
presence of CD63, CD81, CD34, GAPDH, CD200, CD44 and
CD105 using western blots as previously described [14]. Briefly,
10 mg of exosomes were lysed with Laemmli sample buffer (Bio-
Rad Laboratories, Hercules, CA, USA), separated on 7–15%
SDS/PAGE gels and transferred onto PVDF membrane (Milli-
pore, Billerica, MA, USA) for western blot analysis. Membranes
were incubated overnight at 4uC with antibodies specific for:
CD63 (1:200, sc-15363, Santa Cruz, CA, USA), CD34 (1:2000,
ab81289, Abcam, Cambridge, MA, USA), CD81 (1:200, PA5-
13582, Thermo Fisher, Pittsburgh, PA, USA), GAPDH (1:500,
FL-335, Santa Cruz, CA, USA), CD200 (1:2000, AF2724, R&D,
Minneapolis, MN, USA), CD44 (1:1000, ab41478, Abcam,
Cambridge, MA, USA), CD105 (1:1000, ab169545, Abcam,
Cambridge, MA, USA), platelet IIb/IIIa (1:200, sc-73544, Santa
Cruz, CA, USA). Next, the HRP-conjugated secondary antibody
(1:5000, Pierce, Thermo Fisher, Pittsburgh, PA, USA) was added
for 1 hr at room temperature (RT) and blots were developed with
ECL detection reagents (GE Healthcare Biosciences, Pittsburgh,
PA, USA). The intensities of the bands on exposed films were
quantified using Image J software (NIH, USA).
Flow cytometry
Kasumi-1 cells (26105) were labeled with phycoerythrin (PE)-
conjugated anti-CD33, CD34, CD117 or CD81 antibodies (all
Immuno Capture of AML Exosomes
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from Beckman Coulter, Atlanta, GA, USA) for 20 minutes at 4uC
and analyzed using a 4-color Beckman Coulter XL, and data were
analyzed using the Expo32-Software.
Functional studies with captured CD34+ exosomes
Normal human NK cells were co-incubated with isolated
exosomes to determine expression levels of the natural cytotoxicity
receptor NKp46 and of NKG2D on the surface of these cells as
previously described [13.14]. Briefly, NK cells (16105) were co-
incubated for 24 h with CD34+ exosomes captured directly from
1 mL AML plasma or unbound CD34negative exosomes. Then,
flow cytometry for expression of NKG2D or NKp46 was
performed and data expressed as mean fluorescence intensity
(MFI). NK cells incubated in medium without exosomes were used
as controls. Isolation of human NK cells from normal donor buffy
coats using AutoMACS (Miltenyi Biotec, Auburn, CA, USA) was
previously described [13,14]. PE-conjugated anti-NKG2D and
anti-NKp46 antibodies or isotype controls were purchased from
Beckman Coulter (Atlanta, GA, USA).
Results
Immunoaffinity exosome capture
The strategy used for exosome capture from patients’ plasma is
illustrated in Figure 1A. Freshly harvested or frozen/thawed
plasma was processed as shown in Figure 1B, yielding the
captured CD34+exosome fraction and non-captured CD34neg
exosomes.
Characteristics of Kasumi-1 cell line-derived exosomes
Kasumi-1 cell line is a leukemic cell line established from
peripheral blood of an AML patient with 8; 21 chromosome
translocation. It originated from early myeloid stem cell [16,17]
and expresses leukemic blast markers, including CD34, CD33,
CD117 (Figure 2A). Exosomes present in supernatants of cultured
Kasumi-1 cells were initially isolated by ultracentrifugation and
used to implement the strategy shown in Figure 1A. Isolated
Kasumi-1 exosomes floated at density of 1.10–1.14 on a
continuous sucrose density gradient (Figure 2B) and were visual-
ized by TEM as typical cup-shaped vesicles measuring 30–70 nM
in diameter (Figure 2C). In Western blots, their protein profile
included CD34, a blast marker, as well as CD81, the tetraspanin
used as an exosomal marker (Figure 2D). Exosomes isolated from
supernatants of Kasumi cells recapitulated the molecular profile of
the Kasumi cell line (Figure 2D). In addition, Kasumi-1 exosomes
also carried proteins known to be expressed in leukemia stem cells:
CD44, CD200 and CD105 (Figure 2D). Exosomes isolated from
ND plasma were not CD34+ (Figure 2D).
Development of immunocapture using CD34+ exosomes
isolated from Kasumi-1 supernatants
Anti-CD34 Ab-coated microbeads were used to establish
optimal conditions for capture of CD34+ exosomes from
supernatants of Kasumi-1 cells. First, exosomes were isolated
from Kasumi-1 supernatants by ultracentrifugation. The capture
capacity of microbeads was calibrated using densitometric analysis
of western blot bands reactive with anti-CD34 Ab. As shown in
Figure 3A, pixel intensity of each CD34 band linearly correlated
with the exosomal protein level loaded on the SDS/PAGE gel. A 5
to10 mL aliquot of CD34 Ab-coated microbeads was able to
capture all CD34+ exosomes from 20 mg of isolated Kasumi-1
exosomes (Figure 3B, left). The beads capture capacity was not
improved when the bead concentration was increased to 20 mL
(Figure 3B, left). Increasing the protein levels of the input
exosomes linearly correlated with the protein level of captured
CD34+ exosomes (Figure 3B, right and graph). However, capture
efficiency was only about 40% (Figure 3B, graph). To improve
capture efficiency, additional CD34 microbeads were added after
the removal of captured CD34+ exosomes. As shown in Figure 4,
this second step resulted in capture of additional Kasumi-1-derived
CD34+ exosomes, but the final unbound exosomal fraction still
contained CD34+ exosomes. However, AML plasma-derived
CD34+exosomes were completely captured by the first co-
incubation with microbeads (Figure 4). The unbound fraction
did not contain any CD34+ exosomes, although it did contain
other exosomal proteins such as CD81. Control exosomes derived
from ND plasma did not contain CD34+ exosomes. While two
repetitions of immunocapture with 10 mL of CD34 microbeads
Figure 1. The strategy for capture of CD34+ exosomes using anti-CD34 Ab-coated microbeads purchased from Miltenyi (A) and a
schema for capture of CD34+ exosomes directly from AML patients’ plasma (B).
doi:10.1371/journal.pone.0103310.g001
Immuno Capture of AML Exosomes
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e103310
each were necessary to capture about 75% CD34+ exosomes
present in 100 mg of supernatant-derived exosomes, one 10 mL
aliquot of CD34 microbeads was sufficient for capture of all
CD34+ exosomes from 100 mg of exosomes obtained from AML
plasma.
Capture of CD34+ blast-derived exosomes directly from
AML plasma
Anti-CD34 Ab-coated microbeads were next used to capture
exosomes directly from AML patients’ plasma. For direct exosome
capture, an aliquot (0.1–1 mL) of freshly-harvested or frozen/
thawed plasma was co-incubated with a 10 mL aliquot of
microbeads coated with anti-CD34 Ab. CD34+ exosomes were
captured using a magnetic column as described in Materials and
Figure 2. Studies with the Kasumi-1 cell line and with exosomes derived from Kasumi-1 culture supernatants. A) Flow cytometry of
Kasumi-1 cells shows expression of blast markers, CD34, CD117 and CD33 and of CD81 (tetraspanin). Dotted lines indicate isotype controls. B) Kasumi-
1 exosomes were separated on a continuous sucrose density gradient, and the collected gradient fractions were tested in Western blots for CD34 and
CD81. CD34+ and CD81+ exosomes were recovered at the density of 1.10–1.14. C) An electron microscope image of isolated and negatively stained
Kasumi-1 exosomes. D) Western blots of isolated Kasumi-1 exosomes (Kas) and of exosomes isolated from plasma of a normal donor (NC). Each lane
was loaded with 10 mg exosomal protein.
doi:10.1371/journal.pone.0103310.g002
Figure 3. Calibration experiments with CD34+ Kasumi-1 exosomes isolated by ultracentrifugation. A) Isolated exosomes were loaded at
increasing protein concentrations onto gels and blotted using anti-CD34 Ab. Intensity of each band was measured in pixels. The graph illustrates a
linear relationship between exosomal protein levels and pixel intensity in Western blots. B) Isolated exosomes (20 mg protein) were added to
increasing volumes of CD34 microbeads (left). Five or 10 mL of microbeads were sufficient to capture 20 mg of exosomes. Next, a 10 mL aliquot of
beads was used to capture increasing concentrations of Kasumi-1 exosomes (right). The graph shows that the capacity of CD34 microbeads to
capture up to 80 mg of input exosomes increased linearly. However, at 80 mg only about 40% of exosomal proteins were captured, suggesting that
additional microbeads are necessary for capture of all Kasumi-1 exosomes.
doi:10.1371/journal.pone.0103310.g003
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Methods (Figure 1). The TEM images of the recovered fraction
showed cup-shaped exosomes attached to microbeads (Figure 5A).
The capture capacity of CD34+ exosomes from AML plasma
correlated linearly with the input volume (in mL) of plasma
(Figure 5B). Therefore, using 10 mL of CD34 microbeads, we were
able to capture all CD34+ exosomes from 100 mL to 1000 mL of
AML patients’ plasma. This capture procedure was reproduced
with five different AML plasma- and five ND plasma- derived
exosomes (data not shown). To determine whether protein levels of
captured CD34+ exosomes reflect the percentage of CD34+ blasts
in the peripheral circulation of AML patients, exosomes were
captured from plasma of 5 patients with high or low blast counts as
shown in Figure 5C. Patients with,60% circulating CD34+ blasts
had the highest exosome recovery relative to the patients with
fewer blasts in the periphery. Incidentally, CD34+ exosomes carry
highly variable quantities of CD81, as shown, e.g., in Figure 5C.
For this reason, we prefer to use GAPDH or CD63 as markers of
AML exosomes (Figures 5B or D).
Potential interference of platelet-derived exosomes
Since platelets are one of the major producers of exosomes
found in plasma [15], an attempt was made to determine whether
platelet-derived exosomes non-specifically bind to CD34 microbe-
ads. We attempted to remove platelet-derived exosomes from
plasma using anti-CD61 Ab-coated microbeads. These beads
effectively captured exosomes positive for glycoprotein IIb/IIIa as
seen in Figure 5D (left). Following the removal of CD61+
exosomes, CD34 microbeads were added to the remaining plasma
to capture CD34+ exosomes. The recovered CD34+ exosomes did
not contain glycoprotein IIb/IIIa (Figure 5D, right). This exper-
iment showed that unwanted exosomes, which potentially could
interfere with capture of CD34+ exosomes or compromise their
purity, may be removed by an additional immunocapture step
with selected Ab-coated microbeads.
Characteristics of captured CD34+ blast-derived
exosomes
Western blots of CD34+ exosomes captured from AML patients’
plasma show that in addition to CD34, these exosomes carry
proteins known as AML prognostic markers, including CD105
and CD200 (Figure 6A). The same markers were detected in
exosomes captured from supernatants of the Kasumi-1 cell line
(Figure 2D).
To determine whether the captured CD34+ exosomes are
biologically active, purified normal human NK cells were co-
incubated with captured CD34+ exosomes or CD34neg exosomes
and analyzed by flow cytometry for expression of NK cytotoxicity
receptors. Captured CD34+ exosomes inhibited NKG2D expres-
sion in the NK cells, while CD34neg exosomes reduced the
expression of NKp46 (Figure 6B). These results indicate that the
CD34+ and CD34neg exosomes have differential effects on NK
cells.
Discussion
The rationale for development of the method for immunocap-
ture of AML blast-derived exosomes from plasma of patients with
CD34+ AML is based on existing evidence for selective ability of
tumor-derived exosomes (TEX) to mediate immunosuppression
[3–6]. Given that anti-tumor functions of immune cells are critical
for the control of tumor progression in solid and hematological
cancers [18,19]; TEX-mediated immunosuppression could pro-
mote tumor growth and increase the rate of recurrence. Exosomes
present in cancer patients’ plasma are derived from normal as well
as malignant cell, and true biologic effects of such mixed
populations may be difficult to discern. As only TEX are expected
to carry tumor-derived signals responsible for altering functions of
immune cells, capture of TEX and their separation from the bulk
of plasma exosomes is a necessary and potentially important step.
Several studies have previously tried to immunocapture
exosomes from plasma. For example, the widely-advertised
Exotest kit uses a sandwich ELISA in which anti-Rab-5b Abs
are immobilized in wells of 96-well plates and the captured
exosomes are detected with anti-CD63 Abs [20]. For capture of
exosomes in supernatants of colon cancer cell lines, anti-A33 Ab-
coated Dynabeads or anti-EpCAM Ab-coated microbeads have
been used prior to proteomics-based analyses [21,22]. These
studies showed that the immunoaffinity-based capture was the
most effective method for obtaining exosomes suitable for protein
profiling, because these exosomes carried clinically-relevant
tumor-specific proteins.
Based on this rationale and using somewhat different capturing
strategy, we utilized AML patients’ plasma, which was previously
Figure 4. Capture of CD34+ exosomes from total exosomal fractions by CD34+ microbeads. Isolated Kasumi-1 exosomes (Kas) and total
exosome fractions isolated by ultracentrifugation from normal donor plasma (NC) or from CD34+ AML patient plasma (AML) were used for capture
with CD34 microbeads. After the 1st capture and removal of beads, 2nd capture was performed with a fresh aliquot of CD34 microbeads. The final
unbound fractions were ultracentrifuged to collect remaining exosomes. While the 2nd capture was necessary to recover all CD34+ Kasumi-1
exosomes, a single capture was sufficient to recover all CD34+ exosomes from the bulk of exosomes isolated from the AML plasma. There were no
CD34+ exosomes captured from the bulk exosomal fraction isolated from a normal donor’s plasma. CD81 expression indicates that the unbound
fractions still contain CD34neg exosomes.
doi:10.1371/journal.pone.0103310.g004
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shown to be a rich source of exosomes [13,14], to separate CD34+
from CD34neg exosomes. Titration experiments with different
quantities of the anti-CD34 Ab-coated beads and input exosomes
allowed for quantification of the capture method and estimations
of exosome recovery. In fact, the method allows for recovery of
immunocaptured as well as non-captured exosomes and their
comparisons in Western blots or functional assays. The identity of
captured exosomes was confirmed by TEM. In addition, Western
blots of captured exosomes showed they carried not only CD34
but also other AML blast markers in addition to the usual exosome
markers. In AML, several markers are available for identification
of leukemic blasts by flow cytometry or immunohistochemistry,
including CD34, CD33, CD117, CD133, CD90, CD99, CCL-1
and others [2]. Among them, CD34 has been most extensively
studied and shown to be associated with unfavorable outcome
[23]. CD34+ blasts, like primitive leukemic stem cells, are resistant
to apoptosis induced by chemotherapy and can transfer the disease
in xenograft transplant models [2,24,25]. Although CD34 is
Figure 5. Capture of CD34+ blast-derived exosomes directly from AML patients’ plasma. A) Negatively stained electron microscope
images of exosomes captured on CD34 microbeads (* shows a vacant microbead). B) Increasing AML plasma volumes were used for capture of CD34+
exosomes by microbeads and recovered exosomes were studied by Western blots. The graph shows a linear relationship between the input plasma
volumes and pixel densities of captured and blotted CD34+ exosomes. C) Exosomes were captured from plasma samples obtained from five CD34+
AML patients and were analyzed by Western blots. The percentage of leukemic blasts in the peripheral circulation of each of the patients is shown.
CD81 serves as the exosome marker. D) Removal of platelet-derived exosomes from plasma using anti-CD61 Ab-coated microbeads prior to capture
of CD34+ exosomes. Exosomes captured with CD61 microbeads (left: CD61+) and CD34+ exosomes captured after removing CD61+ exosomes (right:
CD61neg/CD34+) are shown in a representative Western blot of three evaluated.
doi:10.1371/journal.pone.0103310.g005
Figure 6. Characteristics of captured exosomes. A) A representative Western blot profile of the captured CD34+ exosomes and of non-captured
CD34neg exosomes which were isolated by ultracentrifugation from the same AML plasma sample. B) After co-incubation of NK cells with CD34+
exosomes captured directly from AML plasma or CD34neg exosomes as described in materials and Methods, NKG2D expression (in MFI) was found to
be down-regulated only with CD34+ exosomes (red) compared to CD34neg exosomes (green) or control without exosomes (blue). The gray peak
denotes isotype control. In contrast, NKp46 expression was down-regulated by co-incubation with CD34neg exosomes.
doi:10.1371/journal.pone.0103310.g006
Immuno Capture of AML Exosomes
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expressed on normal hematopoietic precursor cells, AML blasts
overexpress CD34, and only exosomes isolated from AML
patients’ plasma but not plasma of ND carried CD34. Therefore,
selection of CD34 for immune capture of blast-derived exosomes is
justified. However, only about 40% of AML patients have CD34+
blasts [26,27]. For immunocapture of blast-derived exosomes in
CD34neg AML, beads coated with Abs to other blast markers, e.g.,
CCL-1 or CD99, or beads coated with a mix of several Abs could
be used, pending a further modification of the capturing method.
This strategy should allow for a broader application of this method
to exosome capture in all AML patients.
We developed and optimized this procedure for immunocap-
ture of CD34+ blast-derived exosomes from AML plasma in
expectation that it will provide a specific tool for separation of
tumor-derived immunologically-active exosomes from the bulk of
those present in plasma and for discrimination of their potentially
different biologic activities. Interestingly, preliminary experiments
with NK cells used as targets for exosomes indicated that blast-
derived captured exosomes had distinct biological activity from
that mediated by non-captured exosomes. The former down-
regulated NKG2D but not NKp46 expression levels, while the
latter down-regulated NKp46 but not NKG2D expression levels.
These data suggest that immunocaptured vs non-captured AML
exosomes may have distinct biological effects. Having previously
shown that TGF-b1carried by AML exosomes down-regulates
NKG2D on NK cells [13], we are now attempting to show that
these differential effects might reflect differences in TGF-b1 levels
on CD34+ vs CD34negative exosomes. This is consistent with our
hypothesis that isolation of blast-derived exosomes may be
important for their use as future biomarkers. For AML patients
with CD34+ blasts, this immunocapture method will now be used
to perform molecular profiling of AML blast-derived exosomes
and of non-captured, non-blast derived exosomes. This should
indicate whether blast-derived exosomes could more effectively
serve as indicators of the presence of leukemic blasts in the bone
marrow or as biomarkers of response to therapies. We have
already shown that the protein levels of total plasma exosomes and
their molecular profiles dramatically change in the course of
chemotherapy [14]. These data emphasized the potential clinical
significance of AML plasma-derived exosomes (isolated but not
selectively captured) as a sensitive biological measure of leukemic
blast persistence after chemotherapy and as a potential predictor
of relapse in AML. The ability to immunocapture blast-derived
exosomes is expected to improve the diagnostic and prognostic
potential of exosomes in AML.
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